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SUMMARY 
The synthesis of racemic [2-{(4-Chlorophenyl)(4-iodophenyl)) 
methoxyethyl]-l-piperidine-3-carboxylic acid, (CIPCA) and its 
radioiodinated analog [125I]CIPCA is described. CIPCA was synthesized 
from 4-iodobenzoyl chloride in five steps in 16% overall yield. 
Ammonium sulfate catalyzed solid-state isotopic exchange of CIPCA 
with Na125I provided [1251]CIPCA in 34% isolated radiochemical yield 
at a specific activity of 118 Ci/mmol. [125I]CIPCA demonstrated 
moderate brain extraction and good in vivo radiostability in preliminary 
biodistribution studies conducted in CD-1 mice. [125I]CIPCA is a 
potentially useful radiotracer for study of the GABA uptake system. 
Key Words: GABA uptake inhibitor, Iodine-125, radiotracer, mouse brain uptake, 
SPECT. 
INTRODUCTION 
The neutral amino acid, 7-aminobutyric acid (GABA) is the major inhibitory 
neurotransmitter in the mammalian central nervous system (1,2), Dysfunctions of 
the GABA neuronal system have been implicated in the development of 
neurological disorders such as Huntington's chorea (3), Parkinson's disease (4) and 
epilepsy (5). In particular, reduced synaptic concentrations of GABA are reported to 
be a contributory factor in certain seizure disorders in humans (6). Consequently, 
attention has been directed towards the development of GABA uptake inhibitors as 
an approach to increase synaptic concentrations of GABA (7). 
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Structure-activity-relationship studies on conformationally restricted GABA 
analogs demonstrate that the R stereoisomer of nipecotic acid, (R-(-)3-piperidine- 
carboxylic acid) is an inhibitor of GABA uptake (IC50 = 1.7 pM) with no detectable 
affinity for GABA receptors (8). The hydrophilic nature of nipecotic acid prevents 
significant permeation of the blood-brain-barrier following peripheral 
administration. However, enhancement of brain permeability has been achieved by 
the introduction of lipophilic groups such as a diphenylmethoxyethyl or a 
diphenylbutenyl group at the nitrogen atom of nipecotic acid (9). These derivatives 
often display similar selectivity and, in some instances, increased inhibitor potency 
for the GABA uptake site (9). Two notable examples are the R stereoisomers of the 
bis(3-methyl-2-thienyl) analog, (NO 328) and bis(4-chlorophenyl) analog, 1 (Figure l), 
with in vitro IC50 
respectively (10,ll). 
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FIGURE 1. Structures of GABA uptake inhibitors 
The development of selective, high affinity radioligands for specific 
neurotransmitter binding sites has played a major role in the rapid growth of 
neuropharmacology. However, few radioligands are currently available for study of 
the GABA neuronal system, and development of new ligands in this area has been 
limited mostly to the benzodiazepine subset of the GABA-benzodiazepine receptor 
complex. The synthesis of a 18F-labeled GABA uptake inhibitor has been recently 
reported for positron emission tomography (PET) studies (12). Currently, 3H-labeled 
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(R,S)-nipecotic acid (Kd = 0.62 PM) is the only available radioligand for study of 
GABA uptake sites (13). This tracer has been used to map GABA uptake sites in rat 
brain as well as in postmortem brain tissues of normal and Alzheimers disease 
subjects (14,15). A radioiodinated ligand would offer many advantages over a 
tritium labeled ligand, including a higher specific activity and, therefore, a higher 
sensitivity for labeling very low receptor densities. An added advantage would be 
the possibility of conducting in vivo imaging studies with the corresponding 1231- 
labeled analog using single photon emission computed tomography (SPECT). The 
objective of this study was to develop an 1251 radioiodinated analog of the prototype 
GABA uptake inhibitor 1, and to conduct preliminary in vivo biodistribution 
studies to ascertain its suitability for study of the GABA uptake system. 
RESULTS AND DISCUSSION 
[2-( (4-Chlorophenyl)(4-[ 125Iliodophenyl) tmethoxyethyll-1-piperidine-3- 
carboxylic acid ([125I]CIPCA, Figure l), wherein a single chlorine atom in 1. is 
replaced with iodine-125, was chosen for evaluation (16). CIPCA was prepared via a 
synthetic route starting from 4-iodobenzoyl chloride as outlined in Scheme I. 
Acylation of chlorobenzene with 4-iodobenzoyl chloride under Friedel-Crafts 
conditions afforded 2 in 87% yield. Diborane reduction of the ketone provided the 
alcohol, 3 which was subsequently converted to the corresponding chloro analog 4 
with SOC12 under reflux conditions. Ethyl N-(2-hydroxyethyl)nipecotate (5) was 
synthesized by refluxing ethyl nipecotate, 2-chloroethanol and anhydrous K2CO3 in 
toluene in the presence of tetrabutylammonium iodide as catalyst. Condensation of 
the benzhydryl chloride (4) with 5. in the absence of solvent at 160-170 OC afforded 
the ester 6 as an oil in 55% yield following purification by chromatography. 
Attempts at deprotection of the ester to the corresponding carboxylic acid 2 under 
acid hydrolysis conditions resulted in cleavage of the benzhydryl ether functionality 
(17). Hydrolysis of 6 with aqueous LiOH according to the published procedure (ll), 
however, provided the desired carboxylic acid (CIPCA, 2) in 73% yield. 
The radiosynthesis of [125I]CIPCA was achieved via the (NH4)2S04 catalyzed 
solid state exchange labeling technique as shown in Scheme 2 (18J9). The initial 
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SCHEME 1. Synthesis of ClPCA (z) 
2 
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radiopurity of [1251]CIPCA was 60% (as determined by radio-TLC analysis) the rest of 
the radioactivity representing mostly free [125I]iodide. Attempts at removal of the 
unreacted radioiodide by either Anion exchange chromatography (Amberlite IRA- 
400) or Cation exchange chromatography (Dowex 50W-X8) resulted in substantial 
SCHEME 2. Synthesis of ['251]CIPCA 
clQ 
1 d"""" COOH ~ ~ ' ' ~ 1  (NH4)'S04 ,145 OC* Nd COOH 
/ 
1251 
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losses of product. This was probably due to a strong interaction of the lipophilic 
amino side chain with the polymeric matrix of the resin. Similarly, attempts at 
purification of [125I]CIPCA using a silica Sep Pak under normal phase conditions 
were unsuccessful due to tailing of the labeled compound. Subsequently, use of a 
cyano Sep Pak under reverse-phase conditions provided [125I]CIPCA in 95% 
radiochemical purity with good product recovery. 
[125IJCIPCA displayed moderately good brain extraction (0.82 % of the injected 
dose at 30 min post injection) in preliminary biodistribution studies conducted in 
female CD-1 mice. Thyroid radioactivity concentrations at 4 h post injection 
indicated <1% in vivo deiodination. A slight regional heterogeneity of uptake in 
brain was observed with a cortex to striatum ratio of 1.2 at 30 min. Braestrup and 
coworkers reported a cortex to striatum ratio of 1.53 for the jn vitro specific binding 
(rat brain synaptosomes) of the R stereoisomer of [3H]NO 328 (10). Our studies with 
[125I]CIPCA a) utilized a racemic mixture and b) were not corrected for the non- 
specific binding component, which could account, in part, for the observed lower 
cortex to striatum ratio. Further studies with the R stereoisomer of [125I]CIPCA (ie. 
R configuration at the C-3 carbon of the piperidine ring), in conjunction with 
pharmacological blocking studies, should provide insight into the specificity of the 
- in a binding of this radiotracer in mouse brain. 
In conclusion, we report here the synthesis of an 125I-labeled radiotracer for 
GABA uptake sites which crosses the blood-brain-barrier and has good in vitra and 
vivQ stability. The moderately high specific activity (118 Ci/mmol) of [125I]CIPCA 
is adequate for in vivo studies in small animals. However, for clinical application a 
no-carrier-added synthesis of the corresponding 123I-labeled analog is preferable in 
order to minimize possible pharmacological or toxicity effects (11). [123I]CIPCA is a 
potentially useful radiotracer for scintigraphic visualization of GABA uptake sites in 
brain by single photon emission computed tomography (SPECT). 
EXPERIMENTAL 
Melting points were obtained with a Thomas-Hoover melting point apparatus 
Infrared spectra were recorded on a Perkin-Elmer 727B 
1H-NMR spectra were obtained on a Bruker WM-360 (360 MHz) 
and are uncorrected. 
spectrometer. 
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instrument with tetramethylsilane as internal standard. Mass spectra were obtained 
on a Finnigan 4021 GCMS/DS (low resolution) or a UG70-250-S (high resolution) 
instrument. Na[1251]iodide was obtained from Nordion Ltd, Ontario, Canada as a 
no-carrier-added solution in 0.1N NaOH (pH = 10 - 12). All chemical reagents were 
purchased from Aldrich Chemical Company, Milwaukee, WI. Flash 
chromatography was performed by the method of Still (20). Elemental analyses were 
performed by Spang Microanalytical Laboratories, Eagle Harbor, MI. 
Thin-layer chromatography of the radioactive products were performed on 
Whatman K6F silica gel glass-backed plates (20 cm, 250 p). TLC chromatograms were 
scanned for radioactivity using a Berthold Model LB 2832 TLC - linear analyzer 
equipped with a Model LB 500 data acquisition system. 
HPLC was carried out on a Beckman Instrument Model 344 liquid 
chromatograph equipped with a Beckman Model 155-00 UV detector. Radioactivity 
was monitored with a Radiomatic Instruments Model DR/IC Flo-one radioactive 
flow detector with a Model CU data acquisition system upgrade containing a 340 pL 
solid scintillant cell. 
The radiochemical purity of [125I]CIPCA was determined using a pBondapak 
Cyano column, 10 p, (3.9 x 300 mm) in series with a Cyano guard cartridge 
(Brownlee) with 0.1 M ammonium acetate (pH=6.8):CH3CN (7:3, v/v) as the mobile 
phase at a flow rate of 1.5 mL/min. UV absorbance was monitored at 214 nm. The 
retention time for [1251]CIPCA under these conditions was 8.7 min. Specific activity 
was determined from a standard curve relating mass to UV absorbance peak area 
(19). 
4-Chloro-4'-iodobenzophenone (a 
Aluminum chloride (2.25 g, 16.9 mmol) was added in one portion to a 
suspension of 4-iodobenzoyl chloride (2.25 g, 8.4 mmol) in dry chlorobenzene (15 
mL) at  room temperature under an argon atmosphere. The pale yellow solution 
was then heated at 70 OC (oil-bath) for 3 h and the warm reaction mixture poured 
over a mixture of crushed ice and concentrated HCl (10 mL). The aqueous 
suspension was extracted with CHC13 (3 x 50 mL) and the combined organic layers 
washed successively with aqueous 10% Na2C03 (50 mL), H 2 0  (50 mL) and dried 
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(Na2S04). Removal of the solvent under reduced pressure and recrystallization of 
the residue from EtOH:CHC13 (4:l) afforded 2.5 g (87%) of 2 as white shiny flakes. mp 
169-170 OC [lit(21) 171.2-171.7 OC]. IR (KBr) 1640 cm-l (carbonyl); 1H NMR (CDC13): 
6 7.87 (d, 2H, J = 8.5 Hz), 7.73 (d, 2H, J = 8.5 Hz) 7.51-7.46 (pair of doublets, 4H). Anal. 
Calcd. for C13H8ClIO C, 45.58; H, 2.35. Found: C, 45.61; H, 2.48. 
4-Chloro-4'-iodobenzhydrol @ 
A solution of 2 (2.3 g, 6.71 mmol) in anhydrous THF (25 mL) was treated 
dropwise with stirring at 5 OC (ice-water bath) with a 1.0 M solution of BH3 in THF 
(13.4 mL, 13.4 mmol). The solution was warmed to room temperature, stirred for 3 
h and quenched by the slow addition at 0 OC of a solution of 50 mL of THF:H20 (1:l). 
The reaction mixture was poured into saturated aqueous K2CO3 (100 mL), extracted 
with Et20 (2 x 100 mL) and dried (MgS04). Flash chromatography [silica-gel, 
hexanes:EtOAc (4:1)] of the crude product gave 2.04 g (88%) of 3 as a white solid 
which was crystallized from hexanes: mp 98-99 OC. IR (KBr) 3340 cm-1 (OH). 1H 
NMR (CDC13): 6 7.65 (d, 2H, J = 8.4 Hz), 7.31-7.24 (pair of doublets, 4H), 7.08 (d, 2H, J = 
8.5 Hz), 5.72 (d, lH, J = 3.2 Hz), 2.37 (d, lH, J = 3.4 Hz). Anal. Calcd. for C13HioCIIO: 
C, 45.31; H, 2.92. Found: C, 45.11; H, 2.97. 
4-Chloro-4'-iodobenzhydryl chloride (4) 
A solution of 3 (2.0 g, 5.8 mmol) in dry CHC13 (20 mL) was treated in one 
portion under argon with excess SOC12 (20 mL) and refluxed for 18 h. Following 
removal of volatiles under reduced pressure the residue was partitioned between 
CHC13 (100 mL) and H20 (50 mL). The aqueous layer was further extracted with 
CHC13 (100 mL), and the combined organic layers dried (Na2S04), filtered, and 
evaporated under reduced pressure. Flash chromatography of the crude product 
[silica-gel; hexanes:EtOAc (19:1)] gave a white crystalline solid: 1.47 g (70%) which 
was recrystallized from hexane: mp 63-65 OC. 1H NMR (CDC13): 6 7.66 (d, 2H, J = 8.5 
Hz), 7.36-7.22 (m, 4H), 7.10 (d, 2H, J = 8.5 Hz), 6.00 (s, 1H). Anal. Calcd. for C13HgC121: 
C, 43.01; H, 2.50. Found: C, 43.13; H, 2.63. 
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Ethyl N-(2-Hydroxyethy1)nipecotate (9 
A refluxing, stirred, slurry of ethyl nipecotate (1.0 g, 6.4 mmol), anhydrous 
K2CO3 (1.8 g, 12.7 mmol), and tetrabutylammonium iodide (0.23 g, 0.64 mmol) in dry 
toluene (10 mL) was treated dropwise with a solution of 2-chloroethanol (0.51 g, 6.4 
mmol) in dry toluene (10 mL) and refluxed for a further 4 h. The mixture was 
filtered while hot, the residue washed with hot toluene (30 mL) and the combined 
organic extracts dried (MgS04). Removal of solvent under reduced pressure and 
flash chromatography of the residue [silica-gel; CHC13:CH30H:NH40H (19:1:0.1)] 
gave 0.93 g (73%) of a clear colorless oil. 1H NMR (CDC13): 6 4.15 (4, 2H), 3.61 (m, 
2H), 2.88 (d, lH), 2.71 (d, lH), 2.57 (m, 3H), 2.41 (t, lH), 2.21 (t, lH), 1.90 (m, lH),  1.76 
(m, lH), 1.58 (t, 2H), 1.26 (t, 3H). 
Ethyl-l-[2-( (4-chlorophenyl)(4-iodophenyl))methoxyethyl]piperidine-3-carboxylate 0 
The nipecotate ester derivative 5 (0.55 g, 2.70 mmol) and 4 (1.0 g, 2.7 mmol) 
were combined in a 5 mL Pierce Reacti-vial, the vial sealed with a teflon-lined cap 
and heated in an oil bath a t  160-170 O C  for 45 min. The warm reaction mixture was 
solubilized in hot THF (5 mL) and poured into a mixture of 100 mL of ether: 
saturated brine (1:l). The organic layer was removed, the aqueous layer further 
extracted with ether (2 x 50 mL), and the combined organic layers dried (Na2S04). 
Removal of solvent under reduced pressure and flash chromatography [silica-gel; 
CHC13:CH30H (197:3)] of the residue afforded 0.80 g (55%) of a pale yellow oil. 
IR (Nujol) 1728 cm-1 (carbonyl). 1H NMR (CDC13): 6 7.64 (d, 2H, J = 8.4 Hz), 7.26 (dd, 
4H, J = 8.6 Hz) 7.06 (d, 2H, J = 8.5 Hz), 5.28 (s ,  lH), 4.11 (q, 2H, J = 7.1 Hz), 3.55 (t, 2H, J = 
5.9 Hz), 3.01 (d, lH), J = 8.0 Hz), 2.76 (d, lH, J = 11.3 Hz), 2.65 (t, 2H, J = 5.9 Hz), 2.54 (m, 
lH), 2.24 (t, lH, J = 10.6 Hz), 2.08 (dt, lH), 1.94 (dd, lH, J = 11.4 Hz), 1.69 (m, lH), 1.62- 
1.39 (m, 2H), 1.23 (t, 3H, J = 7.1 Hz). HRMS (CI with CH4) MH+ at 528.0786 (Calcd 
528.0802). Anal. Calcd. for C23H27ClIN03: C, 52.33; H, 5.26; N, 2.65. Found: C, 52.34; 
H, 5.25; N, 2.64. 
[2-( (4-Chlorophenyl)(4-iodophenyl~)methoxyethyll-l-piperidine-3-carboxylic acid (2) 
A mixture of 6 (0.15 g, 0.3 mmol) and a 1.0 M solution of aqueous LiOH (0.5 
mL, 0.5 mmol) in CH30H (5 mL) was refluxed with stirring at 65 OC until 
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homogenous (1 h). The cooled mixture was poured into H20 (20 mL), extracted with 
EtOAc (3 x 50 mL), and the organic layer dried (Na2SOq). Removal of solvent under 
reduced pressure and flash chromatography of the residue [silica-gel; CHC13: CH30H: 
N H 4 0 H  (7:3:0.1)] gave 0.11 g (73%) of an amorphous solid. IR (KBr) 1710 cm-1 
(carbonyl); 1H NMR (CD3COCD3): 6 7.71 (d, 2H, J = 7.9 Hz); 7.43 (d, 2H, J = 8.4 Hz), 
7.36 (d, 2H, J = 8.2 Hz) 7.24 (d, 2H, J = 7.9 Hz), 5.51 (s, lH), 3.62 (t, 2H), 2.87-2.42 @r m, 
7H), 1.85-1.51 (br m, 4H). HRMS (CI with CH4) MH+ at 500.0477 (Calcd 500.0489). 
Anal. Calcd. for C21H23ClIN03: C, 50.47; H, 4.64; N, 2.80. Found: C, 50.29; H, 4.67; N, 
2.82. 
[2-{ (4-Chlorophenyl)(4-[~~~I]iodophenyl))methoxyethyl]-l-piperidine-3-carboxylic 
acid (1125IlCIPCA; [125IIa 
[125I]CIPCA was synthesized by (NH&S04 catalyzed isotopic exchange as 
follows: A solution of (NH4)2S04 (6 mg in 20 pL of deionized H20), 2 (20 pg in 40 
pL of acetone), Na125l (7.8 mCi in 16p1 of 0.1N NaOH), and three layers of 3 mm 
borosilicate glass beads were combined in a 3 mL multi-dose vial, and the mixture 
was heated in an oil bath to 145 OC over a 25 min period. At this point 20 cc of air 
was slowly introduced into the reaction vial by syringe over a 2 min period, and the 
dry reaction mixture was maintained at 145 O C  for an additional 25 min. The vial 
was cooled and radio-TLC analysis performed [silica; CHC13: CH30H: NH40 H 
(7:3:0.1)]. The Rf of [1251]2 and NaI25I were 0.23 and 0.55 respectively in this TLC 
system, and the radiochemical purity of the product was 60%. Further purification 
was achieved by chromatography on a cyano Sep Pak (Waters). The crude product 
(7.1 mCi) in EtOH (0.50 mL) was diluted with H 2 0  (10 mL) and transferred to an 
activated cyano Sep Pak [prewashed with CH30H (5 mL) followed by H 2 0  (5 mL)]. 
The Sep Pak was rinsed sequentially with 0.01% aqueous NaI (5 mL) and H 2 0  (5 mL) 
to remove residual Na125I. Following sequential rinsing of the Sep Pak with 
CH30H:H20 (1:9, v/v; 5 mL) and CH30H:H20 (1:4, v/v; 5 mL), elution with 100% 
CH30H (2 x 1 mL) afforded 2.65 mCi of [125I]CIPCA with a radiochemical purity of 
95%. Isolated radiochemical yield was 34% and the specific activity was determined 
to be 118 Ci/mmol. The solvent was removed using an argon stream, the product 
redissolved in absolute EtOH to a concentration of 1 mCi/mL and stored at 4 OC until 
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further use. Under these conditions, the labeled product showed less than 5% 
radiolytic decomposition in 48 h by radio-TLC and radio-HPLC analysis. The 
radiotracer was formulated in 0.150 M sodium acetate (pH = 4.5):EtOH (95:5, v/v) for 
animal evaluation. 
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